UBS Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.7M Buy
5,101,237
+1,409,215
+38% +$5.45M ﹤0.01% 2857
2025
Q4
$15.1M Sell
3,692,022
-61,756
-2% -$306K ﹤0.01% 2869
2025
Q3
$18.3M Sell
3,753,778
-876,812
-19% -$4.6M ﹤0.01% 2671
2025
Q2
$23.4M Sell
4,630,590
-939,192
-17% -$4.61M ﹤0.01% 2212
2025
Q1
$29.5M Buy
5,569,782
+2,565,137
+85% +$18.7M 0.01% 1970
2024
Q4
$20.3M Buy
3,004,645
+2,204,785
+276% +$14.8M ﹤0.01% 2303
2024
Q3
$5.27M Sell
799,860
-849,190
-51% -$6.09M ﹤0.01% 3016
2024
Q2
$12.4M Buy
1,649,050
+976,619
+145% +$8.52M ﹤0.01% 2052
2024
Q1
$6.7M Sell
672,431
-19,480
-3% -$217K ﹤0.01% 2646
2023
Q4
$6.82M Buy
691,911
+349,232
+102% +$2.49M ﹤0.01% 2439
2023
Q3
$2.62M Buy
342,679
+173,954
+103% +$1.74M ﹤0.01% 3183
2023
Q2
$1.26M Sell
168,725
-210
-0.1% -$1.47K ﹤0.01% 4012
2023
Q1
$1.13M Sell
168,935
-192,960
-53% -$1.53M ﹤0.01% 4004
2022
Q4
$2.79M Buy
361,895
+343,430
+1,860% +$3.37M ﹤0.01% 3046
2022
Q3
$196K Buy
18,465
+13,479
+270% +$137K ﹤0.01% 5099
2022
Q2
$41K Sell
4,986
-1,941
-28% -$13K ﹤0.01% 6076
2022
Q1
$49K Sell
6,927
-252,295
-97% -$2.68M ﹤0.01% 6523
2021
Q4
$4.44M Buy
259,222
+188,079
+264% +$3.54M ﹤0.01% 2953
2021
Q3
$1.64M Buy
71,143
+70,443
+10,063% +$2M ﹤0.01% 3750
2021
Q2
$26K Buy
+700
New +$20.7K ﹤0.01% 7079

Other funds holding RXRX